A new drug treatment for type 2 diabetes that combines metformin with the DPP-4 inhibitor linagliptin in a single tablet is now available in the UK.
Boehringer Ingelheim and Eli Lilly’s combination drug Jentadueto is designed to improve blood glucose control, alongside a healthy diet and exercise, in adults with type 2 diabetes who are unable to control their condition with metformin alone or metformin and a sulphonylurea, or those already being treated with the combination of linagliptin and metformin .
Jentadueto was approved in Europe in July following data from Phase III clinical trials, which showed that a twice-daily dose of the oral medication (2.5mg linagliptin/1000mg metformin) caused a significant reduction in blood sugar levels, compared to use of metformin (1000mg twice-daily) or linagliptin (5mg once-daily).
In addition, the single-pill treatment did not cause any significant change in body weight and was generally well-tolerated.
Speaking earlier this month, Professor Klaus Dugin, Corporate Senior Vice President of Medicine at Boehringer, said: “We’re delighted that linagliptin/metformin hydrochloride (HCl) will soon be available across Europe to help people with type 2 diabetes .
“Many patients need more than one treatment to adequately manage their diabetes. Linagliptin/metformin hydrochloride (HCl) offers a simplified, single tablet dosing option, to improve glycaemic control and with a favourable side effect profile.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…